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Phospholipase A2s (PLA2s) are a group of enzymes that hydrolyze the sn-2 position of phospholipids to
release (typically unsaturated) fatty acids and lysophospholipids, which serve as precursors for a variety
of bioactive lipid mediators. Among the PLA2 superfamily, secreted PLA2 (sPLA2) enzymes comprise the
largest subfamily that includes 11 isoforms with a conserved HiseAsp catalytic dyad. Individual sPLA2
enzymes exhibit unique tissue and cellular localizations and speciﬁc enzymatic properties, suggesting
their distinct biological roles. Recent studies using transgenic and knockout mice for individual sPLA2
isofoms have revealed their involvement in various pathophysiological events. Here, we overview the
current state of knowledge about sPLA2s, speciﬁcally their roles in mast cells (MCs) in the context of
allergology. In particular, we highlight group III sPLA2 (PLA2G3) as an “anaphylactic sPLA2” that promotes
MC maturation and thereby anaphylaxis through a previously unrecognized lipid-orchestrated circuit.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
The mammalian genome encodes more than 30 phospholipase
A2s (PLA2s) or related enzymes, which are classiﬁed into several
structurally related families including the intracellular cytosolic
PLA2 (cPLA2) and Ca2þ-independent PLA2 (iPLA2) families and the
secreted PLA2 (sPLA2) family. The sPLA2 family typically consists of
low molecular mass, Ca2þ-requiring enzymes bearing a HiseAsp
catalytic dyad. Classically, sPLA2s have been found abundantly in
snake or insect venom. In mammals, there are 11 sPLA2s (IB, IIA, IIC,te of Medical Science, 2-1-6
. Murakami).
ety of Allergology.
rgology. Production and hosting by ElsIID, IIE, IIF, III, V, X, XIIA and XIIB), which are subdivided into a
conventional group (I, II, V and X) and two atypical groups (III and
XII).1,2 Individual sPLA2s have distinct substrate speciﬁcities and
tissue distributions, suggesting their distinct, non-redundant roles.
Indeed, recent studies using sPLA2 transgenic or knockout mice
have revealed that individual sPLA2s exert their speciﬁc functions
by producing lipid mediators, by altering the composition of
membrane phospholipids, by degrading foreign phospholipids in
microorganisms or dietary components, or by modifying extracel-
lular non-cellular lipid components (lipoproteins, lung surfactant
or microvesicles) in response to given microenvironmental cues.
Current understanding of the in vivo functions of sPLA2s has been
summarized in recent reviews.1e5 Here, we will make an overview
of the biological roles of sPLA2s and the underlying lipid pathways
in allergy, focusing on mast cells (MCs) which occupy a central role
in allergic responses.evier B.V. All rights reserved.
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Crosslinking of the high-afﬁnity IgE receptor Fc 3RI on MCs with
IgE and antigen initiates signals leading to the release of allergic
mediators that induce immediate hypersensitivity.3 MCs produce
prostaglandin (PG) D2 and leukotrienes (LTs) B4 and C4 as lipid
mediators, with preferential production of PGD2 by connective-
tissue MCs (CTMCs) and LTs by mucosal MCs (MMCs). IL-3-driven
bone marrow-derived MCs (BMMCs), a relatively immature MC
population, produce LTC4 in preference to PGD2, thus resembling
MMCs. The roles of these eicosanoids in allergy are well docu-
mented by other reviews (see reviews by Kabashima and Yoko-
mizo) in this journal issue.
Numerous studies have demonstrated that cPLA2a, which
translocates from the cytosol to perinuclear membranes in
response to an increase in cytosolic Ca2þ and is phosphorylated and
activated by mitogen-activated protein kinases, is essential for the
stimulus-coupled release of arachidonic acid (AA) from phospho-
lipids and thereby production of eicosanoids in many cell types
includingMCs.4,5 Indeed, mice lacking cPLA2a (Pla2g4a/) or those
treated with a cPLA2a inhibitor show attenuated asthmatic re-
sponses upon pulmonary antigen challenge,6e8 and BMMCs from
Pla2g4a/ mice show impaired production of PGD2, LTs and
platelet-activating factor, a lysophospholipid-derived lipid medi-
ator that also participates in allergic responses.9,10
Studies using IL-3-driven BMMCs as a model system have
revealed that eicosanoid generation by MCs occurs in multiple
phases. The immediate response, which occurs within a few mi-
nutes, involves explosive activation of cPLA2a followed by prompt
conversion of AA to PGH2 and then to PGD2 through the sequential
action of cyclooxygenase (COX)-1 and hematopoietic PGD2 syn-
thase (H-PGDS) and to LTA4 and then to LTC4 through that of 5-
lipoxygenase (5-LOX) in cooperation with 5-LOX-activatingFig. 1. cPLA2a-dependent eicosanoid biosynthesis in MCs. Following Fc 3RI crosslinking, cP
in response to Stim1/Orai1-mediated Ca2þ inﬂux and is phosphorylated by mitogen-activ
phospholipids by cPLA2a is then converted to PGD2 by the sequential action of cyclooxy
matopoietic PGD2 synthase (H-PGDS) to PGD2 or by the sequential action of 5-lipoxygenase
to LTC4.protein and LTC4 synthase11 (Fig. 1). The delayed response, which
proceeds over several hours, depends entirely on sustained acti-
vation of cPLA2a coupled with de novo induction of COX-2.10,12,13 In
a third (or priming) phase, culture of BMMCs with stem cell factor
(SCF; a ligand for c-Kit) in the presence of accessory cytokines (e.g.
IL-3, IL-4, IL-9 and IL-10) for several days not only facilitates MC
proliferation, but also partially supports MC maturation toward a
PGD2-producing CTMC-like phenotype through increased expres-
sion of cPLA2a, COX-1 and H-PGDS.14 On the other hand, IL-3 in-
creases the expression of cPLA2a, 5-LOX and LTC4 synthase,
allowing MCs to exhibit a LTC4-producing MMC-like phenotype.15
Whereas LTs produced by MCs are pro-allergic,16 PGD2 produced
by H-PGDS in MCs exhibits anti-allergic rather than pro-allergic
effects in anaphylaxis and contact hypersensitivity.17,18
Compared to culture with SCF alone, coculture of BMMCs with
ﬁbroblasts in the presence of SCF facilitates more efﬁcient matu-
ration toward a CTMC-like phenotype in terms of the appearance of
mature granules with greater amounts of histamine and proteases,
higher cell surface expression of Fc 3RI, and the eicosanoid balance
shift from LTs to PGD2.17,19,20 The latter process is characterized by
increased expression of cPLA2a, COX-2 and H-PGDS as well as LTB4
dehydrogenase, an enzyme that inactivates LTB4, and decreased
expression of LTA4 hydrolase (LTB4 synthase) and LTC4 synthase.21
During the BMMC-ﬁbroblast coculture, PGE2, which exerts an
anti-allergic effect via the PGE2 receptor EP3,22e26 is produced by
ﬁbroblasts in a manner dependent upon cPLA2a in BMMCs, where
cPLA2a -driven AA is transferred to adjacent ﬁbroblasts through the
transcellular route and then metabolized to PGE2 by micosomal
PGE2 synthase (mPGES-1).23 Mice null for mPGES-1 (Ptges/) or
EP3 (Ptger3/) display more severe allergic responses.22e26 Para-
doxically, PGE2-EP3 signaling induces inﬂammatory swelling by
directly activating MCs.27 Therefore, the anti-allergic action of PGE2
may rely on EP3 signaling in stromal cells rather than in MCs.LA2a translocates from the cytosol to the perinuclear (preferentially Golgi) membrane
ated protein kinase (MAPK) for optimal activation. The AA released from membrane
genase (COX)-1 (or COX-2 when the cells are primed by particular stimuli) and he-
(5-LOX) in corporation with 5-LOX-activating protein (FLAP) and LTC4 synthase (LTC4S)
M. Murakami, Y. Taketomi / Allergology International 64 (2015) 4e106BMMCs also express iPLA2b abundantly, and it has been re-
ported that the pharmacologic inhibition of iPLA2b by bromoenol
lactone, a well-known iPLA2 inhibitor, attenuates degranulation,
eicosanoid production and cytokine release by BMMCs.28 However,
mice deﬁcient in iPLA2b (Pla2g6/) showed a normal MC-
dependent anaphylactic response in vivo and Pla2g6/ BMMCs
exhibit normal effector functions in vitro,23 arguing against the
contribution of iPLA2b to MC differentiation, maturation and acti-
vation. Thus, caution should be exercised when interpreting the
results obtained from studies using bromoenol lactone or any other
PLA2 inhibitors.
sPLA2s and MCs: a historical view
It has been proposed that sPLA2s, after being secreted, may act
on plasma membrane phospholipids in neighboring cells (para-
crine) or in their cells of origin (autocrine) to augment lipid
mediator synthesis. However, this concept has yet to be substan-
tiated because in vivo evidence has been largely lacking. Several
reports have also suggested that sPLA2s exert intracellular effects
(before secretion or after internalization),29e31 although the phys-
iological relevance of this concept remains obscure. Despite the
longer history of research on sPLA2s in comparison with intracel-
lular PLA2s, the roles of sPLA2s in various biological processes,
including MC-dependent allergy, have remained a mystery for
more than two decades.
From a historical viewpoint, sPLA2 and MCs were ﬁrst linked in
the early 1990s, soon after the molecular identiﬁcation of group IIA
sPLA2 (PLA2G2A or sPLA2-IIA), an isoform that was originally pu-
riﬁed from platelets or from synovial ﬂuid of patients with rheu-
matoid arthritis.32e34 As PLA2G2A (often called “inﬂammatory
sPLA2”) is secreted from activated platelets, researchers have been
interested in the roles of this enzyme in other hematopoietic cells
including neutrophils, macrophages and MCs. Immunohistochem-
istry of rat serosal CTMCs has revealed the location of PLA2G2A in
secretory granules,35 although the speciﬁcity of the antibody
employed in that study was unclear. We have attempted to purify
PLA2 enzymes expressed in BALB/c BMMCs or rat mastocytoma
RBL-2H3 cells using classical column chromatography strategies
and identiﬁed three distinct PLA2 activities.36 One enzyme was
identiﬁed as cPLA2a and another enzyme appeared to be similar to
PLA2G2A in terms of several enzymatic and biochemical properties,
while the entity of the third enzyme has yet to be identiﬁed. Cell
biological studies have shown that degranulation rather than
eicosanoid generation by rat peritoneal CTMCs is suppressed by
several sPLA2 inhibitors,37,38 and exposure of these cells to very
high concentrations of exogenous PLA2G2A triggers histamine
release39 or PGD2 generation.40 BMMCs rapidly internalized and
degraded PLA2G2A through a heparan sulfate proteoglycan-
dependent process.41 Moreover, during the delayed response,
Pla2g2a mRNA was induced in parallel with delayed PGD2 pro-
duction in BALB/c BMMCs.42,43 However, it was subsequently found
that C57BL/6 BMMCs displayed normal activation despite the
intrinsic absence of PLA2G2A due to a frameshift mutation,44 and
together with the fact that the sPLA2 family contains 11 isoforms,1,2
the precise contribution of PLA2G2A to MC activation remained
ambiguous.
Soon after the identiﬁcation of group V sPLA2 (PLA2G5 or sPLA2-
V) in the mid 1990s,45 Reddy et al. reported that PLA2G5 was
abundantly expressed in BMMCs and released from these cells after
antigen-induced activation, acting on neighboring ﬁbroblasts to
augment COX-1-dependent PGD2 biosynthesis.46e48 This idea
seemed fascinating because it was the ﬁrst indication that sPLA2
had a paracrine action, and it was even speculated that the role
previously assigned to PLA2G2A was actually attributable toPLA2G5. Later, it was demonstrated that PLA2G2A and PLA2G5 had
different intracellular locations in BMMCs, with the former existing
in secretory granules and the latter in the perinuclear Golgi,49
suggesting their distinct roles. Using BMMCs from Pla2g5/
mice, Arm and coworkers showed that PLA2G5 ampliﬁed cytokine
induction of COX-2 and attendant delayed generation of PGD2 in
C57BL/6, but not BALB/c, BMMCs50 and that PLA2G5 enhanced
TLR2-, but not Fc 3RI-dependent, eicosanoid generation in BMMCs
through ampliﬁcation of cPLA2a activation.51 Thus, PLA2G5 might
control some MC-dependent processes related to innate immunity
under certain in vivo conditions. However, recent studies have
argued against these observations, since the expression of PLA2G5
in BMMCs proved to be rather low and MC activation both in vivo
and in vitro was not affected in Pla2g5/ mice.17,23
Back in the late 1990s, by which time all conventional sPLA2
isoforms had been cloned,52 we performed transfection assays of
nearly a full set of conventional sPLA2s using RBL-2H3 cells in order
to gain insight into their potential actions in MCs. Overexpression
of PLA2G2A augmented degranulation, where immunoreactive
PLA2G2A was localized in secretory granules of resting cells and
redistributed to sites of granular and plasma membrane fusion in
activated cells, suggesting that PLA2G2A might produce fusogenic
lysophospholipids in situ, thereby facilitating MC exocytosis.53
Transfection of other conventional sPLA2s also augmented
degranulation or eicosanoid generation to various degrees.54e56
Although these results argue for the potential roles of conven-
tional sPLA2s in MCs, their endogenous expression was undetect-
able or detected at only trace levels in mouse BMMCs.17 Moreover,
MC-dependent anaphylaxis was unaffected in Pla2g2d/,
Pla2g2e/, Pla2g2f/, Pla2g5/ and Pla2g10/ mice.17 Thus,
studies employing super-physiologic overexpression or addition of
sPLA2s do not appear to precisely reﬂect the physiologic, or even
pathologic, situation, and the results obtained so far clearly need to
be interpreted with caution. As described below, a clearer picture of
the role of sPLA2 in MC biology has emerged after the generation
and analysis of Pla2g3/mice, which lack group III sPLA2 (PLA2G3
or sPLA2-III), an atypical sPLA2 that was ﬁrstly cloned in 200057 and
whose enzymatic and biological properties have been character-
ized only partially.58,59
Group III sPLA2, a regulator of MC maturation
Bee venom PLA2 (bvPLA2), a major bee venom component that
induces anaphylaxis, is an atypical form of sPLA2.60,61 When
injected into mouse skin, bvPLA2 cleaves membrane phospholipids
to release lysophosphatidylcholine, which causes cell lysis, leading
to activation of group 2 innate lymphoid cells by releasing the Th2-
promoting cytokine IL-33.62 The aggravated Th2-dominant IgE
response to bvPLA2 can be interpreted as a protective mechanism
against future exposure to this noxious venom component. The sole
homolog of bvPLA2 in the mammalian genome is
PLA2G3.57e59,61,63,64 Given these facts, we hypothesized that
PLA2G3may function as an endogenous counterpart of bvPLA2, and
in fact we have found that PLA2G3 is a long-sought sPLA2 that
participates in the regulation of MCs.17
Exogenous PLA2G3, like bvPLA2, elicits MC activation in mouse
skin,17 and transgenic overexpression of human PLA2G3 leads to
spontaneous skin inﬂammation.65 PLA2G3 is expressed more
abundantly than conventional sPLA2s in mouse BMMCs, where it is
stored in secretory granules and released upon cell activation.
Importantly, MC-associated passive and active anaphylactic re-
sponses are markedly attenuated in Pla2g3/mice and conversely
augmented in Pla2g3-transgenic mice.17 BMMCs from Pla2g3/
mice fail to reconstitute the anaphylactic response after transfer to
MC-deﬁcient KitW-sh/W-sh mice, indicating that the defect caused by
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Pla2g3/ mice are numerically normal but morphologically and
functionally immature. In fact, the histamine and protease contents
of granules, expression of MCmaturation markers such as histidine
decarboxylase (HDC, a histamine synthase) and H-PGDS, and cell
surface expression of Fc 3RI are considerably lower in Pla2g3/MCs
than inwild-type cells, suggesting that PLA2G3 does not merely act
as a MC activator, but also facilitates MC maturation. Consistent
with this, Pla2g3/ BMMCs exhibit defective ﬁbroblast-directed
maturation, and thereby IgE-dependent and even -independent
activation, releasing lower levels of histamine and PGD2, in ex vitro
culture. Microarray analysis has further underscored the matura-
tion defects in Pla2g3/ MCs (Fig. 2).
In an effort to identify the lipid mediator pathway acting
downstream of PLA2G3 toward MC maturation, we used 27
knockout mouse lines deﬁcient in biosynthetic enzymes or re-
ceptors for eicosanoids.17 Strikingly, MC abnormalities similar to
those in Pla2g3/ mice were also seen in mice lacking lipocalin-
type PGD2 synthase (L-PGDS) or those lacking the PGD2 receptor
DP1, suggesting the functional coupling of these components in a
common signaling pathway. Supporting this, pharmacological or
genetic ablation of DP1 in MCs or L-PGDS in ﬁbroblasts pheno-
copies that of PLA2G3 in MCs in terms of defective MC maturation
and anaphylaxis. Taken together, we conclude that PLA2G3
secreted from immatureMCs is coupled with ﬁbroblastic L-PGDS to
provide microenvironmental PGD2, which in turn acts on DP1 on
MCs to promote their appropriate maturation (Fig. 3).
It is well known that the SCF/c-Kit system, in cooperation with
several transcription factors, adhesion molecules or accessory cy-
tokines, is crucial for development, homing, proliferation and dif-
ferentiation of MCs.66e71 However, as SCF alone is insufﬁcient to
fully drive the terminal maturation of MCs, it has been hypothe-
sized that some other stromal factor(s) may be additionally
required. Our study has revealed that a signal driven by PGD2Fig. 2. Microarray analysis of Pla2g3¡/¡ BMMCs in comparison with wild-type BMMCs. IL
or without Swiss3T3 ﬁbroblasts in the presence of SCF to allow maturation to CTMC-like
induced in Pla2g3þ/þ CTMC-like cells compared to replicate BMMCs. Approximately 61% of t
heat map of the microarray analysis (B) and a list of representative genes that were affecteprovides a missing link required for the ﬁbroblast-driven matura-
tion of MCs. Thus, the PLA2G3/L-PGDS/DP1 axis represents a novel
lipid-orchestrated mechanism, highlighting a new aspect of PGD2-
DP1 signaling in promotingMCmaturation and thereby allergy, and
providing a rationale for the long-standing issue of why the
secreted type of PLA2 is needed. The paracrine PLA2G3/L-PGDS/DP1
circuit driving the proper maturation of MCs cannot be compen-
sated by other PLA2 subtypes, implying the speciﬁc role of this
atypical sPLA2.sPLA2 and human MCs: additional insights
It is important to translate the results obtained from animal
studies into humans. Human skin MCs show PLA2G3 immunore-
activity, and marked expression of PLA2G3 mRNA is detected in
human lung or skin MCs.17 Expression of HDC mRNA is robustly
induced in human lung MCs after coculture with human lung ﬁ-
broblasts, and this is suppressed by pharmacological inhibition of
PLA2G3, L-PGDS or DP1. Thus, the ﬁbroblast-directed maturation of
human MCs also depends on the PLA2G3/L-PGDS/DP1 circuit.
It should be noted that MC heterogeneity in humans is more
complex than that in rodents. It has been shown that PLA2G2D is
weakly expressed in human cord blood-derived MCs.72 Triggiani
et al. reported that lung MCs from asthmatic patients constitutively
expressedmRNAs for group IB, IIA, IID, IIE, IIF, III, V, X, XIIA, and XIIB
sPLA2s, and that the cell-impermeable conventional sPLA2 inhibitor
Me-Indoxam partially reduced the production of LTC4 from anti-
IgE-stimulated human lung MCs.73 Considering that Me-Indoxam
does not inhibit atypical sPLA2s, these results suggest that some
conventional sPLA2s released from human lung MCs might
contribute to LTC4 production in an autocrine fashion. It remains
unclear whether PLA2G3 is involved in the maturation of all MC
subsets in distinct human tissues andwhether other sPLA2s, such as
PLA2G2A, which is expressed far more abundantly than other-3-driven BMMCs from Pla2g3þ/þ and Pla2g3/mice were co-cultured for 4 days with
cells (A). Of more than 40,000 genes detected so far by microarray, 3652 genes were
hese inducible genes (2223 genes) were downregulated in Pla2g3/ CTMC-like cells. A
d by Pla2g3 deﬁciency (C) are indicated.
Fig. 3. Regulation of MC maturation through the paracrine PLA2G3/L-PGDS/DP1 circuit. PLA2G3 released from immature MCs acts on neighboring ﬁbroblasts to promote L-
PGDS-dependent generation of PGD2, which in turn acts on the PGD2 receptor DP1 on MCs to promote MC maturation. PLA2G3 released from mature MCs may also augment
degranulation. As such, PLA2G3 facilitates MC-dependent anasphylaxis. Expression levels of cPLA2a and H-PGDS are increased in mature MCs to supply a distinct pool of PGD2 that
negatively controls anaphylaxis.
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could functionally substitute for PLA2G3 or have other roles.
Concluding remarks
In this article, we have provided an overview of more than 20
years of studies on sPLA2s in MCs conducted by both our group and
others. On the basis of the dogma prevailing in PLA2 research, most
investigators used to speculate that sPLA2 might be involved in
some phases of eicosanoid production by MCs, even after the
central role of cPLA2a in this process had been established. The
discovery of PLA2G3 has greatly expanded our understanding of
sPLA2 as a regulator of MC maturation via a paracrine PGD2 loop.17
Besides the regulation of MCs and allergy, accumulating evidence
suggests that sPLA2 generally acts as a paracrine coordinator of
various pathophysiological events by driving a unique form of lipid
metabolism in response to a speciﬁc microenvironmental
cue.63,74,75
There are, however, several questions to be answered. Firstly, is
PLA2G3 the only sPLA2 involved in the regulation of MCs or MC-
associated allergic diseases? Since we used only limited criteria
with which to evaluate the functions of MCs,17 investigation of
other parameters, such as host defense against parasites or bacte-
ria, might reveal a yet unidentiﬁed role of PLA2G3 or other sPLA2s
in MCs. In fact, PLA2G2A acts as a potent “bactericidal sPLA2” by
degrading the cell membranes of Gram-positive bacteria,76 and
some constituents of MC granules such as proteases have a pro-
tective role against exogenous venom components.77 Secondly,
does PLA2G3 regulate more complex chronic allergic diseases such
as asthma or atopic dermatitis? Although it has been reported that
Pla2g5/ or Pla2g10/mice exhibit reduced airway inﬂammation
in asthma models,78,79 the role of PLA2G3 in asthma is currently
unknown. It is noteworthy that PLA2G5 is a “Th2-prone sPLA2” that
promotes Th2 immunity by facilitating M2 polarization ofmacrophages,74,80 whereas PLA2G10 appears to be secreted from
airway epithelial cells and then to act on neighboring leukocytes to
augment the generation of eicosanoids.81 Considering that MCs
have been implicated in obesity and atherosclerosis,82,83 the role of
PLA2G3 in these metabolic diseases would also be worth exam-
ining. Thirdly, is PLA2G3 expressed in immune cells other than
MCs? Our preliminary study has revealed the expression of PLA2G3
in non-MC immune cell populations (unpublished data), which
might also affect the pathology of allergic or other immune dis-
eases. Lastly, speciﬁc inhibitors for PLA2G3 are currently unavai-
lable, which limits our understanding of the efﬁcacy of targeting
this enzyme for disease therapy. Given the unique structural fea-
tures of PLA2G3,84 its inhibitor would require rather strict speci-
ﬁcity, and its application would give further insight into the unique
and important roles of this atypical sPLA2 in mouse disease models
as well as human diseases.
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